8-K: Danimer Scientific Faces Delisting from NYSE, Shifts to OTCQX Market

Danimer Scientific's stock will be delisted from the NYSE due to not meeting market capitalization requirements and will begin trading on the OTCQX market.

Summary

• Danimer Scientific received notice from the New York Stock Exchange (NYSE) that it will be delisted due to not maintaining an average global market capitalization of at least $15 million over 30 consecutive trading days.
• Trading of Danimer's Class A common stock on the NYSE was suspended after market close on December 30, 2024.
• The company is evaluating whether to appeal the delisting decision.
• If no appeal is made or if an appeal is unsuccessful, the NYSE will file a Form 25 with the SEC, leading to delisting ten days after the filing.
• Danimer's stock is expected to begin trading on the OTCQX Market on December 31, 2024, under the ticker symbol 'DNMR'.
• There is no guarantee that the stock will continue to trade on the OTCQX Market or that sufficient trading volume will exist.
• The transition to the OTCQX Market is not expected to impact the company's business operations or SEC reporting obligations.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting) and raises concerns about the company's financial stability and future prospects. The move to the OTCQX market is a downgrade and introduces additional risks.

Positives

• The company's business operations are not expected to be affected by the delisting.
• The company will continue to trade on the OTCQX market, maintaining some level of trading for investors.
• The company will continue to meet its SEC reporting obligations.

Negatives

• The company failed to maintain the minimum market capitalization required for NYSE listing.
• The company's stock has been suspended from trading on the NYSE.
• There is no guarantee that the stock will continue to trade on the OTCQX Market or that sufficient trading volume will exist.
• The company faces potential risks associated with trading on the OTCQX Market, including liquidity constraints and limited regulatory oversight.

Risks

• There are potential risks associated with trading on the OTCQX Market, including liquidity constraints and limited regulatory oversight.
• The company's ability to maintain sufficient liquidity is a concern.
• The company's indebtedness may restrict current and future operations.
• There is substantial doubt regarding the company's ability to continue as a going concern.
• The company faces risks related to its ability to meet any requirements of any stock exchange for listing its securities in the future.
• The company is exposed to general economic conditions and other factors affecting consumer confidence, preferences, and behavior.
• The company is exposed to disruption and volatility in the global currency, capital, and credit markets.
• The company is exposed to the financial strength of the company's customers.
• The company is exposed to the company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof.
• The company is exposed to risks relating to the uncertainty of the projected financial information with respect to the company.
• The company is exposed to the ability of the company to execute and integrate acquisitions.
• The company is exposed to changes in governmental regulation, legislation or public opinion relating to our products.
• The company is exposed to product liability or product warranty claims and other loss contingencies.
• The company is exposed to the outcomes of any litigation matters.
• The company is exposed to the impact on our business, operations and financial results from the ongoing conflicts in Ukraine and the Middle East.
• The company is exposed to the impact that global climate change trends may have on the company and its suppliers and customers.
• The company is exposed to the company's ability to protect patents, trademarks and other intellectual property rights.
• The company is exposed to any breaches of, or interruptions in, our information systems.
• The company is exposed to the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes.
• The company is exposed to our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems.
• The company is exposed to the impact of adverse publicity about the company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception.
• The company is exposed to fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations.
• The company is exposed to our ability to utilize potential net operating loss carryforwards.
• The company is exposed to changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks.

Future Outlook

The company is assessing whether to appeal the NYSE's delisting decision and expects its stock to trade on the OTCQX market. The company acknowledges risks associated with OTCQX trading and its ability to maintain liquidity and meet future listing requirements.

Management Comments

• The company is currently assessing whether to appeal the NYSE's delisting determination.
• The transition to the OTCQX Market is not expected to affect the company's business operations or its current SEC reporting obligations.

Industry Context

The delisting highlights the challenges faced by companies in the bioplastics sector, particularly in maintaining market capitalization and investor confidence. It also underscores the importance of financial stability and operational performance in a competitive market.

Comparison to Industry Standards

• Many companies in the bioplastics sector are still in the development and growth phase, and some face challenges in achieving profitability and maintaining market capitalization.
• Compared to established chemical companies, Danimer is a relatively young company and is more susceptible to market volatility and financial pressures.
• Other companies in the bioplastics space, such as NatureWorks and Novamont, have also faced challenges in scaling up production and achieving profitability, but have not faced delisting from major exchanges.
• The delisting of Danimer from the NYSE is a significant setback compared to industry peers that have maintained their listings.

Stakeholder Impact

• Shareholders will experience a loss of value and increased risk due to the delisting and move to the OTCQX market.
• Employees may face uncertainty about the company's future.
• Customers and suppliers may have concerns about the company's long-term viability.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will assess whether to appeal the NYSE's delisting decision.
• The company's stock is expected to begin trading on the OTCQX Market on December 31, 2024.
• The company will continue to monitor its financial performance and market conditions.

Key Dates

Keywords

delisting, NYSE, OTCQX, market capitalization, trading suspension, bioplastics, DNMR, common stock